Will NOACs become the new standard of care in anticoagulation therapy?
International Journal of the Cardiovascular Academy · 2015
DOI: 10.1016/j.ijcac.2015.06.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of the Cardiovascular Academy, 2015. Verfasst von Ergene Oktay. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Atrial fibrillation Warfarin Oral anticoagulantsAtrial fibrillation is the most common cardiac arrhythmia in the general population, with a prevalence of 1-3%, which increases with age, reaching 15% in elderly people.Prophylaxis of ischemic stroke with warfarin was the gold standard of medical management for many years.On the other hand heparin and warfarin was the main pharmacologic agents for the prophylaxis/treatment of venous thromboembolism.In the last 5 years warfarin is getting replaced by non-vitamin K antagonist oral anticoagulants at least partly.In this article it is attempted to foresee whether new oral anticoagulants will become the new standard of care in anticoagulation therapy.
Zitieren
APA
Oktay, E. (2015). Will NOACs become the new standard of care in anticoagulation therapy?. International Journal of the Cardiovascular Academy. https://doi.org/10.1016/j.ijcac.2015.06.007
Vancouver
Oktay E. Will NOACs become the new standard of care in anticoagulation therapy?. International Journal of the Cardiovascular Academy. 2015. doi:10.1016/j.ijcac.2015.06.007
BibTeX
@article{Oktay2015,
author = {Oktay, Ergene},
title = {Will NOACs become the new standard of care in anticoagulation therapy?},
journal = {International Journal of the Cardiovascular Academy},
year = {2015},
doi = {10.1016/j.ijcac.2015.06.007}
}
EUVIMED